STC-1010 addresses the need for effective therapies in microsatellite stable (MSS) colorectal cancer (CRC), a subtype with low immunogenicity and poor response to immune checkpoint inhibitors.

(RTTNews) - Coherus BioSciences (CHRS) announced a clinical collaboration with STORM Therapeutics (STORM) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI in a Phase 1b/2 study ...